Quantcast

Latest Pharmaceutical sciences Stories

2014-08-11 16:28:15

SARASOTA, Fla., Aug. 11, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it filed with the Securities Exchange Commission its Form 10-Q for the second quarter ended June 30, 2014. The company has also announced a clinical and regulatory update. http://photos.prnewswire.com/prnvar/20140811/135143 Second Quarter, 2014: For the three months ended...

2014-08-11 16:28:03

-- FDA Approval of Omidria(TM) Received on May 30, 2014 - SEATTLE, Aug. 11, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014, which include: -- 2Q...

2014-08-11 16:27:34

REDWOOD CITY, Calif., Aug. 11, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and six months ended June 30, 2014. On July 25, 2014, AcelRx announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's new...

2014-08-11 16:25:35

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Spasticity Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2280943/Spasticity-Global-Clinical-Trials-Review-H2-2014.htmlSpasticity Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Spasticity clinical trial scenario. This report provides elemental information and...

2014-08-11 16:25:21

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Renal Pain Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/703965/Renal-Pain-Global-Clinical-Trials-Review-H2-2014.htmlRenal Pain Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Renal Pain Global Clinical Trials Review, H2, 2014" provides data on the Renal Pain clinical trial scenario. This report provides elemental information and...

2014-08-11 12:28:18

Twenty-five pharmaceutical companies being asked to adopt common principles re biosimilars on patient safety, lobbying and business partnerships. DETROIT, Aug. 11, 2014 /PRNewswire/ -- A coalition of 19 institutional investors representing $430 billion in assets commends Amgen and Novartis for support of a set of investor principles to guide corporate boards on policy and oversight responsibilities related to biosimilar activities. The principles, included in the coalition's Investor...

2014-08-11 12:27:30

FRONTIER SCIENTIFIC ACQUIRES PREMIER AG INDUSTRY SUPPLIER LOGAN, Utah, Aug. 11, 2014 /PRNewswire/ -- Frontier Scientific, Inc. (FSI) announces the expansion of its agricultural products offering through the acquisition of a leading supplier of insect products to provide researchers proven quality solutions for insecticide compound screening, seed development and crop protection. Agricultural expansion is a natural fit for FSI's established areas of expertise in complex supply...

2014-08-11 08:30:05

All studies on track for completion and final study reports by November 2014 MALVERN, Pa., Aug. 11, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has completed patient enrollment for the dermal safety studies and the pivotal pharmacokinetic study related to its investigational product Ztlido (lidocaine patch 1.8%), a...

2014-08-11 08:29:12

Meeting with FDA Clarifies Path Forward CASTLE ROCK, Colo., Aug. 11, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients who are at low risk for appendicitis, will host an investor conference call to discuss business updates, including discussion on the progress of...

2014-08-11 08:28:51

With CE mark in place and FDA-directed studies underway in US, company accelerates market development efforts in US, Canada, Israel, and multiple countries in Europe ENGLEWOOD, Colo., Aug. 11, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis Diagnostics has expanded its academic and pharmaceutical research network to over 25 sites around the world. To date the company has initiated over 17 scientific and clinical research...


Latest Pharmaceutical sciences Reference Libraries

Phytotherapy Research
2012-05-01 10:17:25

Phytotherapy Research is a monthly peer-reviewed scientific journal publishing original research papers, short communications, reviews, and letters on medicinal plant research. Topics include pharmacology, toxicology, and the clinical applications of herbs and natural products in medicine, from case histories to clinical trials, including studies of herb-drug interactions and other aspects of the safety of herbal medicines. Short communications dealing with the pharmacology and screening...

More Articles (1 articles) »
Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related